Valizadeh, N (2011) Imatinib induced facial skin hyperpigmentation in a case of chronic myelogenous leukemia. Shiraz E Medical Journal, 12 (3). pp. 162-164.
|
Text
105820110306.pdf Download (137kB) | Preview |
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
Abstract
Imatinib is a tyrosine kinase inhibitor (TKI) which targets BCR-ABL protein in patients with chronic myelogenous leukemia (CML) and c-kit in patients with gastrointestinal stromal tu-mors (GISTs). Skin hypopigmentation is reported during Imatinib therapy. We present a case of CML who developed skin hyperpigmentation in the face during treatment with Imatinib which found chloasma-like appearance
| Item Type: | Article |
|---|---|
| Additional Information: | cited By 3 |
| Uncontrolled Keywords: | Imatinib, Skin, Hyperpigmentation, Chloasma |
| Subjects: | R Medicine > R Medicine (General) |
| Depositing User: | Unnamed user with email gholipour.s@umsu.ac.ir |
| Date Deposited: | 13 Aug 2017 08:03 |
| Last Modified: | 06 Jul 2019 05:42 |
| URI: | http://eprints.umsu.ac.ir/id/eprint/1150 |
Actions (login required)
 |
View Item |
